A 12-year-old boy was diagnosed with Crohn's disease (CD) of the colon and started on 50 mg (1.3 mg/kg) of 6-mercaptopurine (6-MP) daily. His thiopurine S-methyltransferase enzyme activity was normal. The 6-MP dose was subsequently increased to 1.9 mg/kg for persistent symptoms. One year later, the patient's 6-thioguanine (6-TGN) concentration had risen to 434 pmol/8 9 10 8 red blood cells (RBCs; normal range 230-400) and the 6-methyl-mercaptopurine concentration was 4,699 pmol/ 8 9 10 8 RBCs. Three years after the patient was started on 6-MP, the leukocyte count had dropped to 3.8 9 1,000/ mm 3 with a platelet count of 118 9 1,000/mm 3 and normal liver aminotransferases. Therapy with 6-MP was discontinued, but the platelet and leukocyte count remained low. A bone marrow biopsy was normal. Since the patient was asymptomatic, he was monitored off medications. Two years later, the patient developed abdominal pain and weight loss. Esophagogastroduodenoscopy revealed esophageal varices and portal hypertensive gastropathy. Colonoscopy revealed severe CD with deep ulcers throughout the colon. Pathology showed severely active chronic colitis with granulomas, but immunostaining for cytomegalovirus (CMV) was negative. Magnetic resonance cholangiopancreatography showed no biliary dilatation. A transjugular liver biopsy revealed features of nodular regenerative hyperplasia with portal fibrosis (Fig. 1 ).
Discussion
The low-power impression of nodularity and early bridging fibrosis suggest non-cirrhotic portal hypertension (NCPH). The differential diagnosis of NCPH includes nodular regenerative hyperplasia (NRH), hepatoportal sclerosis and incomplete septal cirrhosis; however, these entities are heterogeneous with considerable overlap [1] .
The typical diffuse micronodules in NRH formed by alternating atrophic and hyperplastic areas of hepatic parenchyma are not well developed in this biopsy, and the presence of fibrosis typically excludes NRH [2] . While the biopsy shows fibrous expansion, suggesting hepatoportal sclerosis, definitive portal vein sclerosis is not present. To date, there has only been a single case report of hepatoportal sclerosis in a patient with CD treated with 6-MP [3] and another case attributed to azathioprine therapy following renal transplantation [4] . Incomplete septal cirrhosis is characterized by subtle nodules with hypoplastic Suresh Pola and Brigid S. Boland have contributed equally to this work.
portal tracts and hyperplastic hepatocytes with thin septal fibrosis that may be consistent with this biopsy [5] .
Thiopurines such as 6-MP and azathioprine are widely used to treat patients with CD, and thiopurine-related toxicities include bone marrow suppression and druginduced hepatitis. While bone marrow suppression is typically dose dependent, hepatotoxicity can be idiosyncratic in the setting of hypersensitivity and may present with either cholestatic or hepatocellular patterns of injury. In a study on patients treated with thioguanine, a closely related thiopurine, a high proportion of patients showed signs of NRH [6] . Azathioprine is now recognized as a risk factor for the development of nodular regenerative hyperplasia with a risk of 0.5 % at 5 years [7] .
The present case represents an instance of NCPH with overlap features of both NRH and hepatoportal sclerosis. The hepatotoxicity with leukopenia was not reversible with the cessation of 6-MP. The safety of increasing the dose of 6-MP above a maximum of 1-1.5 mg/kg or of azathioprine above a maximum of 2-3 mg/kg has not been established, and dose reduction should be undertaken if 6-TGN concentrations are elevated. Clinicians must carefully monitor liver chemistries and complete blood counts in patients receiving thiopurines for signs of liver disease, including evidence of portal hypertension in the setting of preserved hepatic synthetic function. 
